The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Hematological Malignancies Disease Market Research Report 2025

Global Hematological Malignancies Disease Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1978799

No of Pages : 103

Ask Your Query
Synopsis
The global Hematological Malignancies Disease market was valued at US$ 37910 million in 2023 and is anticipated to reach US$ 54920 million by 2030, witnessing a CAGR of 5.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hematological Malignancies Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematological Malignancies Disease.
Report Scope
The Hematological Malignancies Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hematological Malignancies Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hematological Malignancies Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Affymetrix
SkylineDx
AgenaBio
Signal Genetics
Pfizer
Roche
Sanofi-Aventis
Cancer Genetics Inc
Illumina
NeoGenomics
Exiqon
Regulus Therapeutics
Rosetta Genomics
Sequenta
Takeda Pharma
Celgene
Amgen
Ono Pharma
Abbott
BMS
Mundipharma
Novartis
MorphoSys
Segment by Type
Chemotherapy
Immunotherapy
Targeted Therapy
Radiotherapy
Stem Cell Transplantation
Others
Segment by Application
Leukemia
Lymphoma
Myeloma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hematological Malignancies Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematological Malignancies Disease Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.2.5 Radiotherapy
1.2.6 Stem Cell Transplantation
1.2.7 Others
1.3 Market by Application
1.3.1 Global Hematological Malignancies Disease Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Myeloma
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hematological Malignancies Disease Market Perspective (2019-2030)
2.2 Hematological Malignancies Disease Growth Trends by Region
2.2.1 Global Hematological Malignancies Disease Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hematological Malignancies Disease Historic Market Size by Region (2019-2024)
2.2.3 Hematological Malignancies Disease Forecasted Market Size by Region (2025-2030)
2.3 Hematological Malignancies Disease Market Dynamics
2.3.1 Hematological Malignancies Disease Industry Trends
2.3.2 Hematological Malignancies Disease Market Drivers
2.3.3 Hematological Malignancies Disease Market Challenges
2.3.4 Hematological Malignancies Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematological Malignancies Disease Players by Revenue
3.1.1 Global Top Hematological Malignancies Disease Players by Revenue (2019-2024)
3.1.2 Global Hematological Malignancies Disease Revenue Market Share by Players (2019-2024)
3.2 Global Hematological Malignancies Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hematological Malignancies Disease Revenue
3.4 Global Hematological Malignancies Disease Market Concentration Ratio
3.4.1 Global Hematological Malignancies Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematological Malignancies Disease Revenue in 2023
3.5 Hematological Malignancies Disease Key Players Head office and Area Served
3.6 Key Players Hematological Malignancies Disease Product Solution and Service
3.7 Date of Enter into Hematological Malignancies Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematological Malignancies Disease Breakdown Data by Type
4.1 Global Hematological Malignancies Disease Historic Market Size by Type (2019-2024)
4.2 Global Hematological Malignancies Disease Forecasted Market Size by Type (2025-2030)
5 Hematological Malignancies Disease Breakdown Data by Application
5.1 Global Hematological Malignancies Disease Historic Market Size by Application (2019-2024)
5.2 Global Hematological Malignancies Disease Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hematological Malignancies Disease Market Size (2019-2030)
6.2 North America Hematological Malignancies Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hematological Malignancies Disease Market Size by Country (2019-2024)
6.4 North America Hematological Malignancies Disease Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hematological Malignancies Disease Market Size (2019-2030)
7.2 Europe Hematological Malignancies Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hematological Malignancies Disease Market Size by Country (2019-2024)
7.4 Europe Hematological Malignancies Disease Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hematological Malignancies Disease Market Size (2019-2030)
8.2 Asia-Pacific Hematological Malignancies Disease Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2019-2024)
8.4 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hematological Malignancies Disease Market Size (2019-2030)
9.2 Latin America Hematological Malignancies Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hematological Malignancies Disease Market Size by Country (2019-2024)
9.4 Latin America Hematological Malignancies Disease Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hematological Malignancies Disease Market Size (2019-2030)
10.2 Middle East & Africa Hematological Malignancies Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2019-2024)
10.4 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Affymetrix
11.1.1 Affymetrix Company Detail
11.1.2 Affymetrix Business Overview
11.1.3 Affymetrix Hematological Malignancies Disease Introduction
11.1.4 Affymetrix Revenue in Hematological Malignancies Disease Business (2019-2024)
11.1.5 Affymetrix Recent Development
11.2 SkylineDx
11.2.1 SkylineDx Company Detail
11.2.2 SkylineDx Business Overview
11.2.3 SkylineDx Hematological Malignancies Disease Introduction
11.2.4 SkylineDx Revenue in Hematological Malignancies Disease Business (2019-2024)
11.2.5 SkylineDx Recent Development
11.3 AgenaBio
11.3.1 AgenaBio Company Detail
11.3.2 AgenaBio Business Overview
11.3.3 AgenaBio Hematological Malignancies Disease Introduction
11.3.4 AgenaBio Revenue in Hematological Malignancies Disease Business (2019-2024)
11.3.5 AgenaBio Recent Development
11.4 Signal Genetics
11.4.1 Signal Genetics Company Detail
11.4.2 Signal Genetics Business Overview
11.4.3 Signal Genetics Hematological Malignancies Disease Introduction
11.4.4 Signal Genetics Revenue in Hematological Malignancies Disease Business (2019-2024)
11.4.5 Signal Genetics Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Hematological Malignancies Disease Introduction
11.5.4 Pfizer Revenue in Hematological Malignancies Disease Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Hematological Malignancies Disease Introduction
11.6.4 Roche Revenue in Hematological Malignancies Disease Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Sanofi-Aventis
11.7.1 Sanofi-Aventis Company Detail
11.7.2 Sanofi-Aventis Business Overview
11.7.3 Sanofi-Aventis Hematological Malignancies Disease Introduction
11.7.4 Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2019-2024)
11.7.5 Sanofi-Aventis Recent Development
11.8 Cancer Genetics Inc
11.8.1 Cancer Genetics Inc Company Detail
11.8.2 Cancer Genetics Inc Business Overview
11.8.3 Cancer Genetics Inc Hematological Malignancies Disease Introduction
11.8.4 Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2019-2024)
11.8.5 Cancer Genetics Inc Recent Development
11.9 Illumina
11.9.1 Illumina Company Detail
11.9.2 Illumina Business Overview
11.9.3 Illumina Hematological Malignancies Disease Introduction
11.9.4 Illumina Revenue in Hematological Malignancies Disease Business (2019-2024)
11.9.5 Illumina Recent Development
11.10 NeoGenomics
11.10.1 NeoGenomics Company Detail
11.10.2 NeoGenomics Business Overview
11.10.3 NeoGenomics Hematological Malignancies Disease Introduction
11.10.4 NeoGenomics Revenue in Hematological Malignancies Disease Business (2019-2024)
11.10.5 NeoGenomics Recent Development
11.11 Exiqon
11.11.1 Exiqon Company Detail
11.11.2 Exiqon Business Overview
11.11.3 Exiqon Hematological Malignancies Disease Introduction
11.11.4 Exiqon Revenue in Hematological Malignancies Disease Business (2019-2024)
11.11.5 Exiqon Recent Development
11.12 Regulus Therapeutics
11.12.1 Regulus Therapeutics Company Detail
11.12.2 Regulus Therapeutics Business Overview
11.12.3 Regulus Therapeutics Hematological Malignancies Disease Introduction
11.12.4 Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2019-2024)
11.12.5 Regulus Therapeutics Recent Development
11.13 Rosetta Genomics
11.13.1 Rosetta Genomics Company Detail
11.13.2 Rosetta Genomics Business Overview
11.13.3 Rosetta Genomics Hematological Malignancies Disease Introduction
11.13.4 Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2019-2024)
11.13.5 Rosetta Genomics Recent Development
11.14 Sequenta
11.14.1 Sequenta Company Detail
11.14.2 Sequenta Business Overview
11.14.3 Sequenta Hematological Malignancies Disease Introduction
11.14.4 Sequenta Revenue in Hematological Malignancies Disease Business (2019-2024)
11.14.5 Sequenta Recent Development
11.15 Takeda Pharma
11.15.1 Takeda Pharma Company Detail
11.15.2 Takeda Pharma Business Overview
11.15.3 Takeda Pharma Hematological Malignancies Disease Introduction
11.15.4 Takeda Pharma Revenue in Hematological Malignancies Disease Business (2019-2024)
11.15.5 Takeda Pharma Recent Development
11.16 Celgene
11.16.1 Celgene Company Detail
11.16.2 Celgene Business Overview
11.16.3 Celgene Hematological Malignancies Disease Introduction
11.16.4 Celgene Revenue in Hematological Malignancies Disease Business (2019-2024)
11.16.5 Celgene Recent Development
11.17 Amgen
11.17.1 Amgen Company Detail
11.17.2 Amgen Business Overview
11.17.3 Amgen Hematological Malignancies Disease Introduction
11.17.4 Amgen Revenue in Hematological Malignancies Disease Business (2019-2024)
11.17.5 Amgen Recent Development
11.18 Ono Pharma
11.18.1 Ono Pharma Company Detail
11.18.2 Ono Pharma Business Overview
11.18.3 Ono Pharma Hematological Malignancies Disease Introduction
11.18.4 Ono Pharma Revenue in Hematological Malignancies Disease Business (2019-2024)
11.18.5 Ono Pharma Recent Development
11.19 Abbott
11.19.1 Abbott Company Detail
11.19.2 Abbott Business Overview
11.19.3 Abbott Hematological Malignancies Disease Introduction
11.19.4 Abbott Revenue in Hematological Malignancies Disease Business (2019-2024)
11.19.5 Abbott Recent Development
11.20 BMS
11.20.1 BMS Company Detail
11.20.2 BMS Business Overview
11.20.3 BMS Hematological Malignancies Disease Introduction
11.20.4 BMS Revenue in Hematological Malignancies Disease Business (2019-2024)
11.20.5 BMS Recent Development
11.21 Mundipharma
11.21.1 Mundipharma Company Detail
11.21.2 Mundipharma Business Overview
11.21.3 Mundipharma Hematological Malignancies Disease Introduction
11.21.4 Mundipharma Revenue in Hematological Malignancies Disease Business (2019-2024)
11.21.5 Mundipharma Recent Development
11.22 Novartis
11.22.1 Novartis Company Detail
11.22.2 Novartis Business Overview
11.22.3 Novartis Hematological Malignancies Disease Introduction
11.22.4 Novartis Revenue in Hematological Malignancies Disease Business (2019-2024)
11.22.5 Novartis Recent Development
11.23 MorphoSys
11.23.1 MorphoSys Company Detail
11.23.2 MorphoSys Business Overview
11.23.3 MorphoSys Hematological Malignancies Disease Introduction
11.23.4 MorphoSys Revenue in Hematological Malignancies Disease Business (2019-2024)
11.23.5 MorphoSys Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Hematological Malignancies Disease Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Immunotherapy
Table 4. Key Players of Targeted Therapy
Table 5. Key Players of Radiotherapy
Table 6. Key Players of Stem Cell Transplantation
Table 7. Key Players of Others
Table 8. Global Hematological Malignancies Disease Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Hematological Malignancies Disease Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Hematological Malignancies Disease Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Hematological Malignancies Disease Market Share by Region (2019-2024)
Table 12. Global Hematological Malignancies Disease Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Hematological Malignancies Disease Market Share by Region (2025-2030)
Table 14. Hematological Malignancies Disease Market Trends
Table 15. Hematological Malignancies Disease Market Drivers
Table 16. Hematological Malignancies Disease Market Challenges
Table 17. Hematological Malignancies Disease Market Restraints
Table 18. Global Hematological Malignancies Disease Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Hematological Malignancies Disease Market Share by Players (2019-2024)
Table 20. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Malignancies Disease as of 2023)
Table 21. Ranking of Global Top Hematological Malignancies Disease Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Hematological Malignancies Disease Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Hematological Malignancies Disease Product Solution and Service
Table 25. Date of Enter into Hematological Malignancies Disease Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hematological Malignancies Disease Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Hematological Malignancies Disease Revenue Market Share by Type (2019-2024)
Table 29. Global Hematological Malignancies Disease Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Hematological Malignancies Disease Revenue Market Share by Type (2025-2030)
Table 31. Global Hematological Malignancies Disease Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Hematological Malignancies Disease Revenue Market Share by Application (2019-2024)
Table 33. Global Hematological Malignancies Disease Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Hematological Malignancies Disease Revenue Market Share by Application (2025-2030)
Table 35. North America Hematological Malignancies Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Hematological Malignancies Disease Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Hematological Malignancies Disease Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Hematological Malignancies Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Hematological Malignancies Disease Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Hematological Malignancies Disease Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Hematological Malignancies Disease Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Hematological Malignancies Disease Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Hematological Malignancies Disease Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Hematological Malignancies Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Hematological Malignancies Disease Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Hematological Malignancies Disease Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Hematological Malignancies Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Hematological Malignancies Disease Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Hematological Malignancies Disease Market Size by Country (2025-2030) & (US$ Million)
Table 50. Affymetrix Company Detail
Table 51. Affymetrix Business Overview
Table 52. Affymetrix Hematological Malignancies Disease Product
Table 53. Affymetrix Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 54. Affymetrix Recent Development
Table 55. SkylineDx Company Detail
Table 56. SkylineDx Business Overview
Table 57. SkylineDx Hematological Malignancies Disease Product
Table 58. SkylineDx Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 59. SkylineDx Recent Development
Table 60. AgenaBio Company Detail
Table 61. AgenaBio Business Overview
Table 62. AgenaBio Hematological Malignancies Disease Product
Table 63. AgenaBio Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 64. AgenaBio Recent Development
Table 65. Signal Genetics Company Detail
Table 66. Signal Genetics Business Overview
Table 67. Signal Genetics Hematological Malignancies Disease Product
Table 68. Signal Genetics Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 69. Signal Genetics Recent Development
Table 70. Pfizer Company Detail
Table 71. Pfizer Business Overview
Table 72. Pfizer Hematological Malignancies Disease Product
Table 73. Pfizer Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 74. Pfizer Recent Development
Table 75. Roche Company Detail
Table 76. Roche Business Overview
Table 77. Roche Hematological Malignancies Disease Product
Table 78. Roche Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 79. Roche Recent Development
Table 80. Sanofi-Aventis Company Detail
Table 81. Sanofi-Aventis Business Overview
Table 82. Sanofi-Aventis Hematological Malignancies Disease Product
Table 83. Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 84. Sanofi-Aventis Recent Development
Table 85. Cancer Genetics Inc Company Detail
Table 86. Cancer Genetics Inc Business Overview
Table 87. Cancer Genetics Inc Hematological Malignancies Disease Product
Table 88. Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 89. Cancer Genetics Inc Recent Development
Table 90. Illumina Company Detail
Table 91. Illumina Business Overview
Table 92. Illumina Hematological Malignancies Disease Product
Table 93. Illumina Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 94. Illumina Recent Development
Table 95. NeoGenomics Company Detail
Table 96. NeoGenomics Business Overview
Table 97. NeoGenomics Hematological Malignancies Disease Product
Table 98. NeoGenomics Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 99. NeoGenomics Recent Development
Table 100. Exiqon Company Detail
Table 101. Exiqon Business Overview
Table 102. Exiqon Hematological Malignancies Disease Product
Table 103. Exiqon Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 104. Exiqon Recent Development
Table 105. Regulus Therapeutics Company Detail
Table 106. Regulus Therapeutics Business Overview
Table 107. Regulus Therapeutics Hematological Malignancies Disease Product
Table 108. Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 109. Regulus Therapeutics Recent Development
Table 110. Rosetta Genomics Company Detail
Table 111. Rosetta Genomics Business Overview
Table 112. Rosetta Genomics Hematological Malignancies Disease Product
Table 113. Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 114. Rosetta Genomics Recent Development
Table 115. Sequenta Company Detail
Table 116. Sequenta Business Overview
Table 117. Sequenta Hematological Malignancies Disease Product
Table 118. Sequenta Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 119. Sequenta Recent Development
Table 120. Takeda Pharma Company Detail
Table 121. Takeda Pharma Business Overview
Table 122. Takeda Pharma Hematological Malignancies Disease Product
Table 123. Takeda Pharma Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 124. Takeda Pharma Recent Development
Table 125. Celgene Company Detail
Table 126. Celgene Business Overview
Table 127. Celgene Hematological Malignancies Disease Product
Table 128. Celgene Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 129. Celgene Recent Development
Table 130. Amgen Company Detail
Table 131. Amgen Business Overview
Table 132. Amgen Hematological Malignancies Disease Product
Table 133. Amgen Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 134. Amgen Recent Development
Table 135. Ono Pharma Company Detail
Table 136. Ono Pharma Business Overview
Table 137. Ono Pharma Hematological Malignancies Disease Product
Table 138. Ono Pharma Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 139. Ono Pharma Recent Development
Table 140. Abbott Company Detail
Table 141. Abbott Business Overview
Table 142. Abbott Hematological Malignancies Disease Product
Table 143. Abbott Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 144. Abbott Recent Development
Table 145. BMS Company Detail
Table 146. BMS Business Overview
Table 147. BMS Hematological Malignancies Disease Product
Table 148. BMS Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 149. BMS Recent Development
Table 150. Mundipharma Company Detail
Table 151. Mundipharma Business Overview
Table 152. Mundipharma Hematological Malignancies Disease Product
Table 153. Mundipharma Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 154. Mundipharma Recent Development
Table 155. Novartis Company Detail
Table 156. Novartis Business Overview
Table 157. Novartis Hematological Malignancies Disease Product
Table 158. Novartis Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 159. Novartis Recent Development
Table 160. MorphoSys Company Detail
Table 161. MorphoSys Business Overview
Table 162. MorphoSys Hematological Malignancies Disease Product
Table 163. MorphoSys Revenue in Hematological Malignancies Disease Business (2019-2024) & (US$ Million)
Table 164. MorphoSys Recent Development
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hematological Malignancies Disease Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Hematological Malignancies Disease Market Share by Type: 2023 VS 2030
Figure 3. Chemotherapy Features
Figure 4. Immunotherapy Features
Figure 5. Targeted Therapy Features
Figure 6. Radiotherapy Features
Figure 7. Stem Cell Transplantation Features
Figure 8. Others Features
Figure 9. Global Hematological Malignancies Disease Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Hematological Malignancies Disease Market Share by Application: 2023 VS 2030
Figure 11. Leukemia Case Studies
Figure 12. Lymphoma Case Studies
Figure 13. Myeloma Case Studies
Figure 14. Others Case Studies
Figure 15. Hematological Malignancies Disease Report Years Considered
Figure 16. Global Hematological Malignancies Disease Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Hematological Malignancies Disease Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Hematological Malignancies Disease Market Share by Region: 2023 VS 2030
Figure 19. Global Hematological Malignancies Disease Market Share by Players in 2023
Figure 20. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Malignancies Disease as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Hematological Malignancies Disease Revenue in 2023
Figure 22. North America Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Hematological Malignancies Disease Market Share by Country (2019-2030)
Figure 24. United States Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Hematological Malignancies Disease Market Share by Country (2019-2030)
Figure 28. Germany Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Hematological Malignancies Disease Market Share by Region (2019-2030)
Figure 36. China Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Hematological Malignancies Disease Market Share by Country (2019-2030)
Figure 44. Mexico Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Hematological Malignancies Disease Market Share by Country (2019-2030)
Figure 48. Turkey Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Hematological Malignancies Disease Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Affymetrix Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 51. SkylineDx Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 52. AgenaBio Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 53. Signal Genetics Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 54. Pfizer Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 55. Roche Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 56. Sanofi-Aventis Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 57. Cancer Genetics Inc Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 58. Illumina Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 59. NeoGenomics Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 60. Exiqon Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 61. Regulus Therapeutics Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 62. Rosetta Genomics Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 63. Sequenta Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 64. Takeda Pharma Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 65. Celgene Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 66. Amgen Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 67. Ono Pharma Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 68. Abbott Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 69. BMS Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 70. Mundipharma Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 71. Novartis Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 72. MorphoSys Revenue Growth Rate in Hematological Malignancies Disease Business (2019-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock